Skip to main content
Erschienen in:

11.06.2019 | Original Article

Resection Combined with TKI Therapy for Resectable Liver Metastases of Gastrointestinal Stromal Tumours: Results from Three National Centres in China

verfasst von: Qichen Chen, Cong Li, Han Yang, Hong Zhao, Jianxiong Wu, Jianjun Zhao, Xinyu Bi, Zhiyu Li, Zhen Huang, Yefan Zhang, Jianqiang Cai, Jianguo Zhou

Erschienen in: Journal of Gastrointestinal Surgery | Ausgabe 6/2020

Einloggen, um Zugang zu erhalten

Abstract

Objective

To investigate the differences in the efficacy of hepatic resection combined with tyrosine kinase inhibitor (TKI) therapy versus TKI therapy alone and the timing of the TKI therapy and hepatic resection for resectable liver metastases from gastrointestinal stromal tumours (GISTs).

Methods

This was a retrospective review of 43 patients confirmed to have resectable liver metastases from GISTs who received TKI treatment alone or the therapy model of hepatic resection combined with TKIs and were admitted to one of 3 institutions between January 2006 and December 2017.

Results

For all liver metastases patients, the 1-, 3- and 5-year survival rates were 97.67%, 88.98% and 66.46%, respectively. The median overall survival (OS) was 85 months. Patients who underwent hepatic resection combined with TKI therapy had a significantly better OS and a trend towards improved progression-free survival (PFS) than patients who received TKIs alone (P = 0.001, mOS 102 months versus 51 months; P = 0.077, mPFS 42 months versus 30 months). Hepatic resection combined with TKI therapy was the only prognostic factor for long-term survival in the multivariate analysis (HR = 0.198, 95% CI 0.048–0.813, P = 0.025). Compared with patients who underwent hepatic resection combined with postoperative TKIs only, patients who underwent hepatic resection combined with perioperative TKIs had a significantly better PFS (P = 0.032, mPFS 29 months versus 19 months) but did not have a significantly better OS (P = 0.662, mOS 92 months versus 102 months). Resection combined with perioperative TKI therapy was the only prognostic factor for PFS in the multivariate analysis (HR = 0.295, 95% CI 0.101–0.862, P = 0.026).

Conclusions

For patients with resectable liver metastases, hepatic resection combined with TKI therapy was more beneficial in terms of improving prognosis than TKIs alone. In terms of the timing of TKI therapy and hepatic resection, resection combined with perioperative TKIs may prolong PFS more than resection combined with postoperative TKIs only.
Literatur
2.
Zurück zum Zitat DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Annals of surgery. 2000;231(1):51–8.CrossRef DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Annals of surgery. 2000;231(1):51–8.CrossRef
3.
Zurück zum Zitat Unalp HR, Derici H, Kamer E, Bozdag AD, Tarcan E, Onal MA. Gastrointestinal stromal tumours: outcomes of surgical management and analysis of prognostic variables. Canadian journal of surgery Journal canadien de chirurgie. 2009;52(1):31–8.PubMedPubMedCentral Unalp HR, Derici H, Kamer E, Bozdag AD, Tarcan E, Onal MA. Gastrointestinal stromal tumours: outcomes of surgical management and analysis of prognostic variables. Canadian journal of surgery Journal canadien de chirurgie. 2009;52(1):31–8.PubMedPubMedCentral
7.
Zurück zum Zitat Chaudhry UI, DeMatteo RP. Advances in the surgical management of gastrointestinal stromal tumor. Advances in surgery. 2011;45:197–209.CrossRef Chaudhry UI, DeMatteo RP. Advances in the surgical management of gastrointestinal stromal tumor. Advances in surgery. 2011;45:197–209.CrossRef
8.
Zurück zum Zitat Park SJ, Ryu MH, Ryoo BY, Park YS, Sohn BS, Kim HJ, Kim CW, Kim KH, Yu CS, Yook JH, Kim BS, Kang YK. The role of surgical resection following imatinib treatment in patients with recurrent or metastatic gastrointestinal stromal tumors: results of propensity score analyses. Annals of surgical oncology. 2014;21(13):4211–7. https://doi.org/10.1245/s10434-014-3866-4.CrossRefPubMed Park SJ, Ryu MH, Ryoo BY, Park YS, Sohn BS, Kim HJ, Kim CW, Kim KH, Yu CS, Yook JH, Kim BS, Kang YK. The role of surgical resection following imatinib treatment in patients with recurrent or metastatic gastrointestinal stromal tumors: results of propensity score analyses. Annals of surgical oncology. 2014;21(13):4211–7. https://​doi.​org/​10.​1245/​s10434-014-3866-4.CrossRefPubMed
9.
Zurück zum Zitat Chen LL, Trent JC, Wu EF, Fuller GN, Ramdas L, Zhang W, Raymond AK, Prieto VG, Oyedeji CO, Hunt KK, Pollock RE, Feig BW, Hayes KJ, Choi H, Macapinlac HA, Hittelman W, Velasco MA, Patel S, Burgess MA, Benjamin RS, Frazier ML. A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer research. 2004;64(17):5913–9. https://doi.org/10.1158/0008-5472.can-04-0085.CrossRefPubMed Chen LL, Trent JC, Wu EF, Fuller GN, Ramdas L, Zhang W, Raymond AK, Prieto VG, Oyedeji CO, Hunt KK, Pollock RE, Feig BW, Hayes KJ, Choi H, Macapinlac HA, Hittelman W, Velasco MA, Patel S, Burgess MA, Benjamin RS, Frazier ML. A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer research. 2004;64(17):5913–9. https://​doi.​org/​10.​1158/​0008-5472.​can-04-0085.CrossRefPubMed
10.
Zurück zum Zitat Antonescu CR, Besmer P, Guo T, Arkun K, Hom G, Koryotowski B, Leversha MA, Jeffrey PD, Desantis D, Singer S, Brennan MF, Maki RG, DeMatteo RP. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clinical cancer research : an official journal of the American Association for Cancer Research. 2005;11(11):4182–90. https://doi.org/10.1158/1078-0432.ccr-04-2245.CrossRef Antonescu CR, Besmer P, Guo T, Arkun K, Hom G, Koryotowski B, Leversha MA, Jeffrey PD, Desantis D, Singer S, Brennan MF, Maki RG, DeMatteo RP. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clinical cancer research : an official journal of the American Association for Cancer Research. 2005;11(11):4182–90. https://​doi.​org/​10.​1158/​1078-0432.​ccr-04-2245.CrossRef
13.
Zurück zum Zitat Bauer S, Rutkowski P, Hohenberger P, Miceli R, Fumagalli E, Siedlecki JA, Nguyen BP, Kerst M, Fiore M, Nyckowski P, Hoiczyk M, Cats A, Casali PG, Treckmann J, van Coevorden F, Gronchi A. Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib -- analysis of prognostic factors (EORTC-STBSG collaborative study). European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2014;40(4):412–9. https://doi.org/10.1016/j.ejso.2013.12.020.CrossRef Bauer S, Rutkowski P, Hohenberger P, Miceli R, Fumagalli E, Siedlecki JA, Nguyen BP, Kerst M, Fiore M, Nyckowski P, Hoiczyk M, Cats A, Casali PG, Treckmann J, van Coevorden F, Gronchi A. Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib -- analysis of prognostic factors (EORTC-STBSG collaborative study). European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2014;40(4):412–9. https://​doi.​org/​10.​1016/​j.​ejso.​2013.​12.​020.CrossRef
14.
Zurück zum Zitat Vassos N, Agaimy A, Hohenberger W, Croner RS. Management of liver metastases of gastrointestinal stromal tumors (GIST). Annals of hepatology. 2015;14(4):531–9.CrossRef Vassos N, Agaimy A, Hohenberger W, Croner RS. Management of liver metastases of gastrointestinal stromal tumors (GIST). Annals of hepatology. 2015;14(4):531–9.CrossRef
15.
Zurück zum Zitat Seesing MF, Tielen R, van Hillegersberg R, van Coevorden F, de Jong KP, Nagtegaal ID, Verhoef C, de Wilt JH. Resection of liver metastases in patients with gastrointestinal stromal tumors in the imatinib era: A nationwide retrospective study. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2016;42(9):1407–13. https://doi.org/10.1016/j.ejso.2016.02.257. Seesing MF and Tielen R shared co-first authorship.CrossRef Seesing MF, Tielen R, van Hillegersberg R, van Coevorden F, de Jong KP, Nagtegaal ID, Verhoef C, de Wilt JH. Resection of liver metastases in patients with gastrointestinal stromal tumors in the imatinib era: A nationwide retrospective study. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2016;42(9):1407–13. https://​doi.​org/​10.​1016/​j.​ejso.​2016.​02.​257. Seesing MF and Tielen R shared co-first authorship.CrossRef
16.
Zurück zum Zitat Shi YN, Li Y, Wang LP, Wang ZH, Liang XB, Liang H, Zhang L, Li B, Fan LQ, Zhao Q, Ma ZX, Zhao XF, Zhang ZD, Liu Y, Tan BB, Wang D, Wang LL, Hao YJ, Jia N. Gastrointestinal stromal tumor (GIST) with liver metastases: An 18-year experience from the GIST cooperation group in North China. Medicine. 2017;96(46):e8240. https://doi.org/10.1097/md.0000000000008240. Shi YN, Li Y and Wang LP shared co-first authorship.CrossRefPubMedPubMedCentral Shi YN, Li Y, Wang LP, Wang ZH, Liang XB, Liang H, Zhang L, Li B, Fan LQ, Zhao Q, Ma ZX, Zhao XF, Zhang ZD, Liu Y, Tan BB, Wang D, Wang LL, Hao YJ, Jia N. Gastrointestinal stromal tumor (GIST) with liver metastases: An 18-year experience from the GIST cooperation group in North China. Medicine. 2017;96(46):e8240. https://​doi.​org/​10.​1097/​md.​0000000000008240​. Shi YN, Li Y and Wang LP shared co-first authorship.CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Blackstein ME, Blay JY, Corless C, Driman DK, Riddell R, Soulieres D, Swallow CJ, Verma S. Gastrointestinal stromal tumours: consensus statement on diagnosis and treatment. Canadian journal of gastroenterology = Journal canadien de gastroenterologie. 2006;20(3):157–63.CrossRef Blackstein ME, Blay JY, Corless C, Driman DK, Riddell R, Soulieres D, Swallow CJ, Verma S. Gastrointestinal stromal tumours: consensus statement on diagnosis and treatment. Canadian journal of gastroenterology = Journal canadien de gastroenterologie. 2006;20(3):157–63.CrossRef
18.
Zurück zum Zitat B Section of Gastrointestinal Surgery CMA, B Section of Colorectal & Anal Surgery, Chinese Medical Association, A CoCCoCA-C, CCoS Chinese Society of Colon & Rectal Surgeons, Chinese Medical Doctors Association, CIEaPAfMaHC Committee of Colorectal Liver Metastases Treatment. Guideline for the diagnosis and comprehensive treatment of colorectal cancer with liver metastases (2016 edition). Chin J Dig Surg. 2016:15(8):755–67. B Section of Gastrointestinal Surgery CMA, B Section of Colorectal & Anal Surgery, Chinese Medical Association, A CoCCoCA-C, CCoS Chinese Society of Colon & Rectal Surgeons, Chinese Medical Doctors Association, CIEaPAfMaHC Committee of Colorectal Liver Metastases Treatment. Guideline for the diagnosis and comprehensive treatment of colorectal cancer with liver metastases (2016 edition). Chin J Dig Surg. 2016:15(8):755–67.
23.
Zurück zum Zitat Demetri GD, Baker LH, Beech D, Benjamin R, Casper ES, Conrad EU, 3rd, DeLaney TF, Ettinger DS, Heslin MJ, Hutchinson RJ, Kiel K, Kraybill WG, Letson GD, Neff J, O'Donnell RJ, Paz IB, Pollock RE, Randall RL, Schupak KD, Tyler DS, von Mehren M, Wayne J. Soft tissue sarcoma clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network : JNCCN. 2005;3(2):158–94.PubMed Demetri GD, Baker LH, Beech D, Benjamin R, Casper ES, Conrad EU, 3rd, DeLaney TF, Ettinger DS, Heslin MJ, Hutchinson RJ, Kiel K, Kraybill WG, Letson GD, Neff J, O'Donnell RJ, Paz IB, Pollock RE, Randall RL, Schupak KD, Tyler DS, von Mehren M, Wayne J. Soft tissue sarcoma clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network : JNCCN. 2005;3(2):158–94.PubMed
24.
Zurück zum Zitat Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, Benjamin RS, Raymond AK, Bramwell VH, Baker LH, Maki RG, Tanaka M, Hecht JR, Heinrich MC, Fletcher CD, Crowley JJ, Borden EC. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008;26(4):626–32. https://doi.org/10.1200/jco.2007.13.4452.CrossRef Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, Benjamin RS, Raymond AK, Bramwell VH, Baker LH, Maki RG, Tanaka M, Hecht JR, Heinrich MC, Fletcher CD, Crowley JJ, Borden EC. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008;26(4):626–32. https://​doi.​org/​10.​1200/​jco.​2007.​13.​4452.CrossRef
Metadaten
Titel
Resection Combined with TKI Therapy for Resectable Liver Metastases of Gastrointestinal Stromal Tumours: Results from Three National Centres in China
verfasst von
Qichen Chen
Cong Li
Han Yang
Hong Zhao
Jianxiong Wu
Jianjun Zhao
Xinyu Bi
Zhiyu Li
Zhen Huang
Yefan Zhang
Jianqiang Cai
Jianguo Zhou
Publikationsdatum
11.06.2019
Verlag
Springer US
Erschienen in
Journal of Gastrointestinal Surgery / Ausgabe 6/2020
Print ISSN: 1091-255X
Elektronische ISSN: 1873-4626
DOI
https://doi.org/10.1007/s11605-019-04278-x

Neu im Fachgebiet Chirurgie

Nur selten ernste Komplikationen bei endoskopischer Sinuschirurgie

Etwa 3% der Menschen mit einer endoskopischen Nasennebenhöhlenoperation entwickeln ausgeprägtes Nasenbluten. Andere Komplikationen, wie Verletzungen des Nervus opticus oder eine Meningitis, treten nur äußerst selten auf, legt eine Registeranalyse nahe.

Hochrisiko-Spinaliom am besten mit der Mohs-Chirurgie entfernen

Die Mohs-Chirurgie ist zwar mit mehr Aufwand verbunden als die herkömmliche Exzision; für die Versorgung kutaner Hochrisiko-Plattenepithelkarzinome lohnt sich die zeitintensive Technik aber in jedem Fall. Laut einer aktuellen Studie sinkt im Vergleich das Sterberisiko.

Mechanische Herzklappe beschert jüngeren Betroffenen längeres Leben

Patienten und Patientinnen bevorzugen bioprothetische Herzklappen gegenüber mechanischen Klappenprothesen. Diese Wahl könnte sich zumindest für jüngere Patienten nachteilig auswirken: Ihnen bietet eine mechanische Klappe anscheinend einen Überlebensvorteil.

Darmpolyp weg – Peptid-Gel gegen Nachblutungen drauf?

Das Nachblutungsrisiko nach einer endoskopischen Mukosaresektion von flachen kolorektalen und duodenalen Adenomen war in der deutschen PURPLE-Studie mit einem hämostatischen Gel nicht kleiner als ohne Prophylaxe.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.